Eculizumab Biosimilar - Research Grade

Eculizumab Biosimilar - Research Grade, Host: Humanized, IgG2/4 kappa

Target: Complement protein C5.

Specificity: Detects human Complement protein C5. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Eculizumab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Eculizumab biosimilar is a recombinant humanized monoclonal IgG2/4κ antibody produced by Chinese hamster ovary cell culture and purified by standard bioprocess technology. Eculizumab biosimilar contains human constant regions from human IgG2 sequences and human IgG4 sequences and murine complementarity-determining regions grafted onto the human framework light- and heavy-chain variable regions. Eculizumab biosimilar is composed of two 448 amino acid heavy chains and two 214 amino acid light chains and has a molecular weight of approximately 148 kDa.

Concentration: 1.0 - 5.0 mg/ml.

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC.

Endotoxin: ≤ 0.75 EU/mg as determined by the LAL method.

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

• SKU: ICH4005-5MG
• Manufacturer: Ichorbio
• Manufacturer SKU: ICH4005-5MG
• Package Unit: 5mg
• Quantity Unit: STK
• Reactivity: Human
• Clonality: Monoclonal
• Isotype: IgG2/4 kappa
• Host: Humanized